Compare Alexandria Real Estate Equities Inc (ARE) vs TG Therapeutics Inc (TGTX) Price & Performance

Alexandria Real Estate Equities (ARE) trades at $48.07, down 0.58% on the day, with a bearish technical signal and mixed earnings. The stock shows negative profitability metrics, including a net income margin of -37.12% and ROE of -6.29%, though it beat FFO estimates in Q2 2026. Recent news highlights leasing momentum and a narrowed full-year FFO guidance range, while a pending lawsuit adds uncertainty.

The outlook remains cautious due to weak earnings and high debt, but the stock trades below book value, offering potential value. Risks include ongoing losses, litigation, and real estate market volatility. Analyst consensus is mixed with a $53.71 price target, suggesting modest upside if operational improvements materialize.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.